Vyepti® (Eptinezumab-jjmr) Prescriber Order Form				
Patient Name: Date of Birth:				
Address:				
Phone:	Height:	□ inches □	cm Weight:	☐ lbs ☐ kg
	Clinical Information	on		
Primary Diagnosis Description:			ICD-10 Code:	
Medications previously tried and failed (list medication and duration of use):			Has patient received Botox®? ☐ Yes, # of injections ☐ No	
	Prescription			
For existing Vyepti patients: Date of last infusion:				
Vyepti® (Eptinezumab-jjmr) refill as directed x 1 year				
☐ Infuse 100 mg IV over 30 minutes once every 3 months				
☐ Infuse 300 mg IV over 30 minutes once every 3 months				
Using a 50ml 0.9% Sodium Chloride IV bag, flush IV tubing with NS 10 to 20 mL after each infusion				
Infuse via a 0.2 micron in-line filter Dispense quantity sufficient of Vyepti® 100 mg single dose vials for each dose				
Ancillary Orders				
Does this patient require an anaphylaxis kit?				
I certify that the use of the indicated treatme			ing the patient's trea	 itment.
Prescriber Signature:			Date:	
	Prescriber Informat	ion		
Prescriber Name:	Phone:		Fax:	
Address:	NPI:			
City, State: Zip:	Office Cont	tact:		
Fax completed form, insurance information, and clinical documentation to:				
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal informatio require authorization. You are obligated to maintain it in a safe, secure, and confidenti obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject.	al manner. Re-disclosure of this inf	ormation is prohibited unless perm	itted by law or appropriate cus	tomer/patient authorization is

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.